Behufs disease is characterized by orogenital ulccrations and ocular lesions, Other features include arthritis, thrombophlebitis, neurological abnormalities and skin lesions. The disease is characterized by a relapsing inflammatory process of unknown aetiology. Lipoprolcin(a) is an LDL-likc particle with a large glycoprotein called apolipoprotein(a) attached to its npolipoprotcin B moiety through one or more clisulphidc bonds. Apolipoprotein(a) is related to plasminogcn from which the cn/yme plasmin, that hydrolyscs fibrin blood clots, is released by tissue plasininogcn activators. The unique structural features of Lp(a) give it the potential for atherogenie and thrombogenic activities. In the present study 35% of patients with /ic j //(.'t'/\s disease were shown to have higher Lp(a) concentrations than the cut-off point (0.30 g/l) for atherosclerosis. Plasma Lp(a) concentrations in the remission period were also found 1ο be lower than during the active period in the same patients (23% decreased). Lp(a) showed significant correlations with acute phase rcaclanls such as crythrocyte sedimentation rate, polymorphonuclcar leukocytes and polymoφhonuclear leukocyte elastase activity. Therefore, it was concluded that the fluclations of plasma Lp(a) levels with the activity of disease may be a contributing risk factor in the development of (hrombogcnic complications in patients with Belief $ disease.
Introduction
development of thrombotic events in Beh^efs disease is ...... ,. ι ι rv // / · n / , thought to be association of defective fibrinolysis (6 (3, 4) . Thrombosis is one ' ô f the vascular manifestations and is seen in about one Lipoprotein(a) [Lp(a)] described by I3et\\> in 1963 const!· third of the patients (5), The basis of thrombosis in the tutcs a newly recognised cardiovascular risk factor with patients is unclear. One of the factors responsible for implications in atherogenie and thrombogcnic processes Bur J Clin Chcm Clin Biochem 1995; 33 (No 8) (8) . The protein moiety of human Lp(a) is composed of apolipoprotein B 10 o and the unique, highly glycosylated glycoprotein apolipoprotein(a), which is heterogeneous in size. The two protein moieties are linked by disulphide bridges. The apolipoprotein(a) gene is highly homologous to plasminogen and contains multiple repeats of a kringle 4 motif. Apolipoprotein(a) exhibits a striking size polymorphism, with the apolipoprotein(a) isoproteins ranging in size from M r 420000 to 840000. Inherited in an autosomal codominant fashion, the apolipoprotein(a) isoprotein is an important factor in determining plasma Lp(a) concentration, with an inverse correlation between the size of the apolipoprotein(a) isoprotein and the plasma Lp(a) concentration (9, 10) . Due to the striking similarity of apolipoprotein(a) to plasminogen, Lp(a) was suggested to act as an interloper in the fibrinolytic system by competing with plasminogen for its binding sites in a dose-dependent manner and inhibiting plasminogen activation (11, 12) . Therefore, elevated plasma Lp(a) levels favour receptor occupancy by the lipoprotein particle and are associated with an increased thrombotic risk. It was reported that plasma Lp(a) levels are influenced by activity of diseases such as myocardial infarction, and by before and after surgical operation, but are hardly affected by diet, age, sex or treatment with lipid-lowering drugs (13 -14) .
In view of the above mentioned data, we have suggested that high Lp(a) levels in patients with Behgefs disease may be a contributing risk factor for the development of thrombotic events (15) . In the present study, we aimed to conform our previous data on the expanded patient group and to clarify the relationship of Lp(a) levels with the disease activity. leukocyte count, erythrocyte sedimentation rate were determined immediately in one aliquot. The second aliquot and blood sample without anticoagulant, that were allowed to clot for l h at room temperature, were centrifiiged at 1500 g for 15 min immediately to obtain plasma or serum samples. The serum samples were divided into two aliquots. 
Materials and Methods
The study group included 45 patients with Behget's disease (male 24 and female 21) with a mean age of 30.8 (age range: 17-55) and 40 healthy volunteers (male 20 and female 20) with a mean age of 31.1 (age range: 17-52). The patient group had a mean body mass index (body weight in kg/squared height in m = kg/m 2 height) of 22.8 ± 5.1 (mean ± SD) which was similar to that of the control group of 23.4 ± 3.9. All the patients were diagnosed separately by the Internal Medicine, Dermatology and Ophthalmology Departments. The diagnosis ofBehgefs disease was made according to the criteria from the International Study Group for Beh$efs disease (16) . The disease activity was evaluated by physical manifestations such as oral aphthous, genital ulcerations, uveitis and vasculitis and appropriate laboratory investigations such as erythrocyte sedimentation rate, polymorphonuclear leukocytes count, polymorphonuclear leukocyte elastase and a 2 -globulins. Six of the patients had thrombotic complications such as superficial thrombophlebitis, which had superimposed segmental thrombosis areas, laying on the veins of lower extremity. At the time of the study, the patients were receiving neither steroids nor lipid-lowering drugs.
Blood samples of 2.5 ml were drawn in collection tubes with EDTA (1 g/1) anticoagulant and of 5 ml in tubes without anticoagulant in the morning by venipuncture after an overnight fast. Anticoagulated blood was divided into two aliquots. Polymorphonuclear
Results
The distribution and concentrations of serum Lp(a) in patients with Behfefs disease and in control subjects are shown in table 1 and figure 1. Plasma Lp(a) concentrations in the patients were significantly higher than those of control group (p < 0.05). Plasma Lp(a) concentrations in patients with Behcefs disease were found to be approximately equal to the cut-off point (0.300 g/1) for a two-fold risk for athefothrombosis (19) and higher than the cut-off point (0.18 g/1) for a twenty-one-fold risk of cerebrovascular disease (20) . According to figure 1, Lp(a) levels of sixteen patients (35%) and six control subjects (15%) were found to be higher than the cut-off point for atherosclerosis. Lp(a) levels were significantly correlated with apolipoprotein B, polymorphonuclear leukocyte and polymorphonuclear leukocyte elastase levels (r = 0.52, p < 0.01; r = 0.39, p < 0.05; r = 0.36, p < 0.05; respectively). The mean serum apolipoprotein A-l a level was significantly lower than in the controls (p < 0.05). Serum apolipoprotein A-I levels were significantly correlated with HDL-cholesterol levels in the patients (r = 0.36, p < 0.05). The mean serum apolipoprotein B level of the patients was significantly higher than that of the control group (p < 0.001). Also, triacylglycerols, HDL-cholesterol and LDL-cholesterol levels in the patients showed significant differences from those of the control group apart from total cholesterol levels.
Other quantities related to the activity of disease in the patients were found to be significantly higher than those of control subjects (tab. 1). The quantities of the patients with thrombotic complications are shown in table 2. Lp(a) and other in these patients were found to be significantly different from the control subjects.
00
Healthy control Behcet's disease Repeated measurements of the Lp(a) and other quantities were made in 10 patients while their disease was active or inactive (tab. 3). During the period of active disease, the mean concentration of Lp(a) was 0.326 g/I and a significantly decreased mean value of 0.250 g/1 was obtained when the disease was inactive. Polymorphonuclear leukocytes, polymorphonuclear leukocyte elastase, a 2 -globulins and erythrocyte sedimentation rate showed significant differences between the active and inactive periods of the disease (p < 0.01). Plasma concentrations of apolipoprotein A-I and HDL-cholesterol were lower, and apolipoprotein Β concentration was higher when the disease was active (data not shown).
Discussion
Plasma Lp(a) levels, which are under genetic control, were highly skewed in the different ethnic groups. It has been reported that the mean Lp(a) value of the Turkish population (0.213 g/1) had a value near to the cut-off point (0.30 g/1) for atheroslcerosis (21) . Also, Beliefs disease is most common in the east part of the Mediterranean. The prevalence of the disease is reported to be 8/10000 in Turkey (22) . It is well known that high plasma Lp(a) level is associated with an increased incidence of cardiovascular and cerebrovascular disease because of its thrombogenic and atherogenic effects. On the endothelial surface, high plasma levels of Lp(a) can interfere with the process of plasminogen-plasmin conversion and result in decreased generation of plasmin and attenuation of clot lysis (23) . Moreover, recent reports showed that Lp(a) has a direct action on endothelial function and induces the production of tissue plasminogen activator inhibitor by endothelium cells (24 is not yet understood. On the other hand, it was reported that the reduced fibrinolytic activity caused by decreased production of tissue plasminogen activator and its increased production by endothelium due to vascular damage may contribute to thrombotic events in the patients (3, 6) . The mean Lp(a) level (0.312 g/1) in patients with Behfefs disease was found to be similar to the cut-off point. The mean Lp(a) level of the patients with thrombotic complications was found to be higher than that of the control group (tab. 2). We believe that the cutoff point of Lp(a) for atherogenesis differs in the various ethnic groups because of the many factors affecting atherogenesis (25) as well as the methodology and standardization problems of Lp(a) measurement. The thrombotic effect of Lp(a) via its apolipoprotein(a) part is dose-dependent because of competitive inhibition with plasminogen (11, 12) . Therefore, Lp(a) may be more important for its thrombotic properties in Behfefs disease since thrombotic events are more common than atherosclerosis in the disease. Sixteen subjects (35.5%) among the patients with Behfet's disease had values higher than the cut-off point, and may therefore be at a much greater risk for thrombo-atherogenesis. It has been previously reported that the thrombotic tendency and the abnormal fibrinolysis is related to the disease activity (6) . Also, Lp(a) is known as an acute phase protein and is significantly correlated with acute phase reactants (13, 14) . The change of plasma Lp(a) concentration was confirmed by the present study in patients with Behgefs disease. Plasma Lp(a) levels in patients with inactive Behfefs disease were found to be decreased by about 23% when compared to the active period of disease. The fluctuations of plasma Lp(a) levels with the activity of the disease may be a contributing risk factor for thrombogenesis in the active period of the disease. There is no effective lipid-lowering drug for Lp(a), the treatment of the active Behfet's patients by appropriate drugs for Behfet's disease may play an important role in lowering the plasma Lp(a) concentration.
Elastase is primarily located in the azurophil granules and is an active component of the phagocytic system of polymorphonuclear leukocytes (26, 27) . Perivascular infiltration of polymorphonuclear leukocytes in Behfefs patients is well known. High plasma polymorphonuclear leukocyte elastase levels, which are more specific than erythrocyte sedimentation rate and a 2 -globulins, may represent the activity of vasculitis in patients (28) . Positive correlations between plasma Lp(a) and polymorphonuclear leukocyte elastase indicate that effects of Lp(a) on development of thrombotic complications may be related to the activity of the disease. Moreover, Lp(a) has an independent effect on the decreased fibrinolysis in patients, and it is also associated with disturbed endothelial functions due to vasculitis.
The decreased concentrations of apolipoprotein A-I, HDL-cholesterol and triacylglycerols found in the patients agree with previous findings (29, 30). High apolipoprotein B levels in patients could be explained by the fact that apolipoprotein B presents chiefly in LDL and Lp(a).
In conclusion, we suggest that plasma Lp(a) concentrations be determined for patients with Behfefs disease, and the patients with high Lp(a) levels be kept under close control, especially during the active period of the disease, and taken into remission as soon as possible.
